Novantrone

Indicated For

prostate cancer, leukemia, multiple sclerosis

About This Medication

# Novantrone Patient Assistance Program Patient Guide: How to Get Novantrone at Low or No Cost This guide explains the **Novantrone Patient Assistance Program** (PAP), offered by Immunex Corporation, which provides **Novantrone (mitoxantrone)**—a chemotherapy drug—for free to eligible uninsured patients facing financial hardship. It covers eligibility, application steps, and key details to help you access this treatment for conditions like multiple sclerosis, leukemia, or prostate cancer.[1][2] ## About Novantrone (Mitoxantrone) **Novantrone** is the brand name for mitoxantrone hydrochloride, a powerful **chemotherapy medication** administered by intravenous infusion in a hospital or clinic.[2] It works by slowing cancer cell growth or suppressing an overactive immune system in multiple sclerosis (MS).[2][4] ### FDA-Approved Uses - **Reducing neurologic disability and clinical relapses** in secondary progressive, progressive relapsing, or worsening relapsing-remitting MS.[3][4] - **Initial therapy** for acute nonlymphocytic leukemia (ANLL).[4] - **Pain relief** in advanced hormone-refractory prostate cancer, combined with corticosteroids.[4] Off-label uses may include other leukemias or lymphomas, but always confirm with your doctor.[6] Novantrone is **not a pill**—it's infused into a vein by your healthcare team, often with a Medication Guide provided before each dose.[2] Keep all follow-up appointments, as missing doses can affect treatment.[2] ### Important Safety Notes This drug can **increase infection risk** (fever, chills, sore throat), cause **bleeding/bruising**, and requires monitoring.[2] It's given in a clinical setting, so your care team handles administration. Discuss heart risks, liver function, and suitability for children with your provider.[2] Novantrone is for you only—do not share it.[2] ## Who Qualifies for the Program? The **Novantrone Patient Assistance Program** helps patients who **cannot afford their medication** and meet strict criteria.[1] While full details like income limits are not publicly disclosed, general eligibility focuses on uninsured status and financial need.[1] ### Key Requirements - **U.S. resident** with a valid prescription for an FDA-approved use. - **No private or public insurance** covering Novantrone—this is a strict rule.[1] - **Financial hardship**, based on undisclosed income guidelines (no specific Federal Poverty Level percentage listed).[1] - Likely requires proof of residency, diagnosis, and household income. Contact the program for personalized eligibility checks, as guidelines may update.[1] ## Income Eligibility Breakdown Income thresholds are **not publicly disclosed** by the program, making it challenging to provide exact figures.[1] Manufacturers often base eligibility on **400% of the Federal Poverty Level (FPL)** or similar, but confirm directly. | Household Size | Estimated Threshold | Notes | |---------------|---------------------|-------| | Individual | Not disclosed | Program reviews case-by-case[1] | | Couple | Not disclosed | Income guidelines private[1] | | Family of 3 | Not disclosed | Call for details[1] | | Family of 4 | Not disclosed | Financial need assessed holistically[1] | **Tip:** Even if near thresholds, apply—exceptions occur for high medical costs.[1] ## Insurance Requirements **No private or public insurance** is allowed for this program.[1] This means: - No Medicare, Medicaid, Tricare, VA benefits, or commercial plans covering Novantrone. - If insured, explore co-pay programs first (none listed here), then reapply if denied coverage. Patients with **Medicare Part D** or other coverage typically don't qualify—verify with your plan.[1][2] ## Step-by-Step Application Process The program supports **multiple application methods** for flexibility.[1] 1. **Get a Prescription:** Ask your oncologist, hematologist, or MS specialist to prescribe Novantrone and complete any required forms.[2][4] 2. **Gather Documents:** Prepare proof of income (tax returns, pay stubs), no-insurance letter, ID, residency proof, and diagnosis summary. Exact list not specified—call to confirm.[1] 3. **Contact the Program:** - **Phone:** 877-447-3243 (main line for applications).[1] - **Fax:** 866-227-3243.[1] - **Address:** 1 Technology Place, Rockland, MA 02370.[1] - No online portal listed; start by phone.[1] 4. **Submit Application:** Doctor or patient faxes/mails it. Multiple methods available (phone-assisted, mail).[1] 5. **Follow Up:** Note confirmation number; processing time not specified—expect 2-4 weeks typically for PAPs.[1] **Pro Tip:** Have your doctor call—they often expedite approvals. ## Timeline and Delivery **Processing time** is not publicly detailed, but patient assistance programs generally review applications in **2-6 weeks**.[1] Once approved, medication ships to your doctor's office or pharmacy for infusion—**delivery method** unspecified, likely standard shipping to provider.[1][2] Track status by calling 877-447-3243. **Reauthorization** may be needed periodically (details unavailable).[1] ## Alternatives if Denied or Ineligible - **Other Foundations:** Patient Advocate Foundation, HealthWell Foundation, or PAN Foundation may cover mitoxantrone.[5] - **Generic Mitoxantrone:** Check 340B hospitals or discount cards if low-income. - **Manufacturer Alternatives:** No biosimilars listed; Immunex (now Amgen?) may have co-pay aid for insured.[1] - **MS Society Resources:** National MS Society lists DMT assistance.[5] - **State Programs:** Medicaid emergency or charity care. - **Clinical Trials:** Search for Novantrone studies via NIH.[6] If denied, request reasons and reapply with more docs. ## Disclaimer This guide is for informational purposes only and based on available data as of program details.[1][2] Eligibility, processes, and availability can change—**always contact the program directly** at 877-447-3243 for current info.[1] Not medical advice; consult your healthcare provider. Immunex Corporation not affiliated with this guide. Word count: 1028.

Program information last verified: March 30, 2026